MedTrace Logo

Dexmedetomidine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy

NCT02031510 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2015-04-06

No results posted yet for this study

Summary

The use of dexmedetomidine as an adjunct to bupivacaine in transversus abdominis plane block will reduce the cumulative morphine consumption after laparoscopic cholecystectomy.

Conditions

  • Elective Laparoscopic Cholecystectomy

Interventions

DRUG

placebo

transversus abdominis plane block with saline 0.9%

DRUG

bupivacaine

transversus abdominis plane block bupivacaine 0.25%

DRUG

bupivacaine-dexmedetomidine

transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1

Sponsors & Collaborators

  • Mansoura University

    collaborator OTHER

  • Imam Abdulrahman Bin Faisal University

    lead OTHER

Principal Investigators

  • Abdulmohsen A Al Ghamdi, MD · Chairman of Anesthesiology Dept

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-02-28
Completion
2015-03-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02031510 on ClinicalTrials.gov